2. Search Result
Search Result
Results for "

medial

" in MedChemExpress (MCE) Product Catalog:

28

Inhibitors & Agonists

1

Fluorescent Dyes

3

Peptides

4

Natural
Products

2

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-W115718
    Cuprizone
    3 Publications Verification

    		 Dopamine β-hydroxylase Neurological Disease
    Cuprizone is a copper chelating agent that forms a deep blue copper ketone complex with copper (II). The copper ketone reaction can be used in colorimetric tests for the presence of trace copper. Cuprizone can be used to induce some schizophrenia-like behavior in mice. Cuprizone acts on copper enzymes, including SOD1, cytochrome oxidase, and DβH, thereby causing oxidative stress and increasing DA levels in certain brain regions such as the medial prefrontal cortex (PFC) .
    Cuprizone
  • HY-B0199A
    Mycophenolate mofetil hydrochloride
    10+ Cited Publications

    RS 61443 hydrochloride; TM-MMF hydrochloride

    		 Interleukin Related Inflammation/Immunology
    Mycophenolate mofetil (RS 61443; TM-MMF) hydrochloride is an orally active antimetabolic immunosuppressant with antiproliferative and anti-inflammatory properties. Mycophenolate mofetil hydrochloride significantly inhibits the production of B, T lymphocytes and the proliferation of smooth muscle cells by selectively blocking the de novo purine synthesis pathway. Mycophenolate mofetil hydrochloride effectively reduces adventitial inflammation, medial necrosis and intimal thickening in rat aortic allografts, and decreases the number of lymphocytes expressing the IL-2 receptor, thereby delaying xenograft rejection. Mycophenolate mofetil hydrochloride shows certain toxicity in a hamster-to-rat limb xenotransplantation model when used in combination with FK506 (HY-13756). Mycophenolate mofetil hydrochloride is widely used in studies related to allograft arteriosclerosis (chronic rejection) .
    Mycophenolate mofetil hydrochloride
  • HY-N8307
    Syringaresinol

    		NO Synthase NF-κB Akt AMPK Calcium Channel Inflammation/Immunology
    Syringaresinol is a lignan-type phytochemical with anti-inflammatory activities. Syringaresinol inhibits the NF-κB and AKT signaling pathway in IL-1β-activated mouse chondrocytes. Syringaresinol increases phosphorylation of AMPK, eNOS, and intracellular Ca 2+ levels in HUVECs. Syringaresinol attenuates osteoarthritis progression in mice with Destabilization of the Medial Meniscus (DMM)-induced osteoarthritis. Syringaresinol can be used for the study of osteoarthritis (OA) .
    Syringaresinol
  • HY-N2411
    Geissoschizine methyl ether
    1 Publications Verification

    		 5-HT Receptor Neurological Disease
    Geissoschizine methyl ether is an orally active, blood-brain barrier permeable alkaloid, and a partial agonist of the 5-HT1A receptor. It can be isolated from Uncaria hook. Geissoschizine methyl ether potently inhibits the binding of [ 3H]8-OH-DPAT to the 5-HT1A receptor in a concentration-dependent manner, with an IC50 of 0.904 μM. It ameliorates isolation-induced increased aggression and reduced sociability in mice. Geissoschizine methyl ether promotes oligodendrocyte differentiation and remyelination in the medial prefrontal cortex of adult mice .
    Geissoschizine methyl ether
  • HY-P1858A
    Urocortin III, mouse TFA

    		CRFR Cardiovascular Disease Neurological Disease Endocrinology
    Urocortin III, mouse TFA is a corticotropin-releasing factor (CRF)-related peptide. Urocortin III preferentially binds and activates CRF-R2 . Urocortin III (Ucn3) is a known component of the behavioral stress response system. Urocortin III and CRF-R2 in the medial amygdala regulate complex social dynamics .
    Urocortin III, mouse TFA
  • HY-141867
    Z-FF-FMK

    Z-Phe-Phe-FMK

    		 Cathepsin MEK Caspase DNA/RNA Synthesis Apoptosis Cardiovascular Disease Neurological Disease
    Z-FF-FMK (Z-Phe-Phe-FMK) is a cell-permeable, irreversible, and cysteine protease inhibitor targeting cathepsin-L. Z-FF-FMK inhibits angiotensin II-induced MEK activation in vascular walls, aortic medial remodeling, blood pressure elevation, and upregulation of cystatin C in aortic walls. Z-FF-FMK prevents β-amyloid-mediated caspase-3 activation, poly (ADP-ribose) polymerase cleavage, DNA fragmentation, and apoptosis of cortical neurons (apoptosis). Z-FF-FMK can be used in research related to hypertension and Alzheimer's disease .
    Z-FF-FMK
  • HY-118301
    ADX71441

    		GABA Receptor 5-HT Receptor Neurological Disease
    ADX71441 is an orally active, blood-brain barrier penetrant positive allosteric modulator of GABAB receptor. ADX71441 potentiates the activity of endogenous GABA at GABAB receptor, with an EC50 of 96 nM. ADX71441 functionally inhibits adenosine transporters and 5-HT2B receptor. ADX71441 produces anxiolytic-like, analgesic, muscle relaxant, hypothermic and overactive bladder inhibitory effects, reduces acute locomotor activity levels, decreases voluntary intake of alcohol and saccharin, attenuates stress-induced neuronal activation, and exhibits anti-hyperalgesic activity .
    ADX71441
  • HY-113995
    (-)-Vesamicol
    1 Publications Verification

    (-)-AH5183

    		 mAChR Neurological Disease
    (-)-Vesamicol (AH5183) is a vesicular acetylcholine transporter inhibitor. (-)-Vesamicol reversibly and non-competitively inhibits the transport of acetylcholine into circulating synaptic vesicles and blocks the activity of vesicular acetylcholine transporters in medial amygdala neurons. (-)-Vesamicol is applicable to research related to central precocious puberty .
    (-)-Vesamicol
  • HY-P1858
    Urocortin III, mouse

    		CRFR Cardiovascular Disease Neurological Disease Endocrinology
    Urocortin III, mouse is a corticotropin-releasing factor (CRF)-related peptide. Urocortin III preferentially binds and activates CRF-R2 . Urocortin III (Ucn3) is a known component of the behavioral stress response system. Urocortin III and CRF-R2 in the medial amygdala regulate complex social dynamics .
    Urocortin III, mouse
  • HY-B0199S
    Mycophenolate Mofetil-d4

    		Isotope-Labeled Compounds Interleukin Related Cancer
    Mycophenolate Mofetil-d4 is the deuterium labeled Mycophenolate Mofetil. Mycophenolate mofetil (RS 61443; TM-MMF) hydrochloride is an orally active antimetabolic immunosuppressant with antiproliferative and anti-inflammatory properties. Mycophenolate mofetil hydrochloride significantly inhibits the production of B, T lymphocytes and the proliferation of smooth muscle cells by selectively blocking the de novo purine synthesis pathway. Mycophenolate mofetil hydrochloride effectively reduces adventitial inflammation, medial necrosis and intimal thickening in rat aortic allografts, and decreases the number of lymphocytes expressing the IL-2 receptor, thereby delaying xenograft rejection. Mycophenolate mofetil hydrochloride shows certain toxicity in a hamster-to-rat limb xenotransplantation model when used in combination with FK506 (HY-13756). Mycophenolate mofetil hydrochloride is widely used in studies related to allograft arteriosclerosis (chronic rejection) .
    Mycophenolate Mofetil-d4
  • HY-106584
    Mosapramine

    Clospipramine

    		 Drug Derivative Dopamine Receptor 5-HT Receptor Neurological Disease
    Mosapramine (Clospipramine) is an orally active antipsychotic agent and one of the metabolites of Clocapramine (HY-B2073) after oral absorption. Mosapramine exerts its effects by specifically binding to striatal dopamine D2 receptors and frontal lobe 5-HT2 receptors, with a D2/5-HT2 receptor occupancy ratio of 7.4. Mosapramine induces typical neuropharmacological responses in rat brain regions, including extrapyramidal symptoms, hyperprolactinemia, increased salivation, constipation, and upregulated Fos protein expression. Mosapramine also features a reduced incidence of weight loss. Mosapramine is applicable to research related to schizophrenia .
    Mosapramine
  • HY-B0199R
    Mycophenolate Mofetil (Standard)

    RS 61443 (Standard); TM-MMF (Standard)

    		 Reference Standards Interleukin Related Cancer
    Mycophenolate Mofetil (Standard) is the analytical standard of Mycophenolate Mofetil. This product is intended for research and analytical applications. Mycophenolate mofetil (RS 61443; TM-MMF) hydrochloride is an orally active antimetabolic immunosuppressant with antiproliferative and anti-inflammatory properties. Mycophenolate mofetil hydrochloride significantly inhibits the production of B, T lymphocytes and the proliferation of smooth muscle cells by selectively blocking the de novo purine synthesis pathway. Mycophenolate mofetil hydrochloride effectively reduces adventitial inflammation, medial necrosis and intimal thickening in rat aortic allografts, and decreases the number of lymphocytes expressing the IL-2 receptor, thereby delaying xenograft rejection. Mycophenolate mofetil hydrochloride shows certain toxicity in a hamster-to-rat limb xenotransplantation model when used in combination with FK506 (HY-13756). Mycophenolate mofetil hydrochloride is widely used in studies related to allograft arteriosclerosis (chronic rejection) .
    Mycophenolate Mofetil (Standard)
  • HY-101377A
    R(+)-8-OH-DPAT hydrobromide

    (R)-8-Hydroxy-2-dipropylaminotetralin hydrobromide

    		 5-HT Receptor Neurological Disease
    R(+)-8-OH-DPAT ((R)-8-Hydroxy-2-dipropylaminotetralin) hydrobromide is a potent 5-HT1A agonist. R(+)-8-OH-DPAT potentiates SUL (HY-B1059)-induced dopamine (DA) release in the medial prefrontal cortex (mPFC) .
    R(+)-8-OH-DPAT hydrobromide
  • HY-W115718R
    Cuprizone (Standard)

    		Reference Standards Dopamine β-hydroxylase Neurological Disease
    Cuprizone is a copper chelating agent that forms a deep blue copper ketone complex with copper (II). The copper ketone reaction can be used in colorimetric tests for the presence of trace copper. Cuprizone can be used to induce some schizophrenia-like behavior in mice. Cuprizone acts on copper enzymes, including SOD1, cytochrome oxidase, and DβH, thereby causing oxidative stress and increasing DA levels in certain brain regions such as the medial prefrontal cortex (PFC) .
    Cuprizone (Standard)
  • HY-120155
    MS-377

    		Sigma Receptor iGluR Neurological Disease
    MS-377 is a selective and orally active sigma-1 receptor ligand (Ki=73 nM) with weak affinity for sigma-2 receptor (Ki=6900 nM) and no affinity for any other receptors including dopamine, serotonin, PCP site, glutamate, γ-aminobutylic acid, adenosine, adrenergic receptors, etc. (Ki: >10 μM). MS-377 indirectly modulates the NMDA receptor ion-channel complex. MS-377 is a antipsychotic agent. MS-377 inhibits PCP-induced behaviors by inhibition of the increase in dopamine and serotonin release in the rat medial prefrontal cortex. MS-377 can be used for research of schizophrenia .
    MS-377
  • HY-B0199AS
    Mycophenolate Mofetil-d4 hydrochloride

    RS 61443-d4 hydrochloride; TM-MMF-d4 hydrochloride

    		 Isotope-Labeled Compounds Interleukin Related Cancer
    Mycophenolate Mofetil-d4 hydrochloride is deuterated labeled Mycophenolate mofetil hydrochloride (HY-B0199A). Mycophenolate mofetil (RS 61443; TM-MMF) hydrochloride is an orally active antimetabolic immunosuppressant with antiproliferative and anti-inflammatory properties. Mycophenolate mofetil hydrochloride significantly inhibits the production of B, T lymphocytes and the proliferation of smooth muscle cells by selectively blocking the de novo purine synthesis pathway. Mycophenolate mofetil hydrochloride effectively reduces adventitial inflammation, medial necrosis and intimal thickening in rat aortic allografts, and decreases the number of lymphocytes expressing the IL-2 receptor, thereby delaying xenograft rejection. Mycophenolate mofetil hydrochloride shows certain toxicity in a hamster-to-rat limb xenotransplantation model when used in combination with FK506 (HY-13756). Mycophenolate mofetil hydrochloride is widely used in studies related to allograft arteriosclerosis (chronic rejection) .
    Mycophenolate Mofetil-d4 hydrochloride
  • HY-131001
    DPNB-ABT594

    		nAChR Neurological Disease
    DPNB-ABT594 is a nitrobenzyl-caged ABT594 (HY-14316A) and activates nAChRs containing the α4β2 subunits with good selectivity than the α7 subunit. DPNB-ABT594 can be used to map the distribution of nAChRs on neurons of the medial habenula (MHb) and helps to gain a deeper understanding of the nAChR-mediated Ca 2+ signalling in the MHb .
    DPNB-ABT594
  • HY-105412A
    RU 52583

    		Adrenergic Receptor Neurological Disease
    RU 52583 is an oral bioactive antagonist of alpha 2-adrenergic receptor. RU 52583 possesses cognition-enhancing properties in rats with damage to the septohippocampal system .
    RU 52583
  • HY-106437
    ELB-139

    		GABA Receptor Neurological Disease
    ELB-139 is a progesterone analogue. ELB-139 is a GABAA receptor partial agonist. ELB-139 has anxiolytic and anticonvulsant activity. ELB-139 induces increase of extracellular 5-HT in the striatum and the medial prefrontal cortex of rats .
    ELB-139
  • HY-105161
    AP-521 free base

    		5-HT Receptor Neurological Disease
    AP-521 (free base) is a benzothienopyridine derivative that exhibits potent anxiolytic effects by acting as a postsynaptic 5-HT1A receptor agonist and by enhancing serotonergic neural transmission in the medial prefrontal cortex (mPFC). AP-521 (free base) is promising for research of anxiety disorders .
    AP-521 free base
  • HY-106153B
    E-5842 citrate

    		Sigma Receptor Neurological Disease
    E-5842 citrate is a σ receptor ligand (Ki: 4 nM for σ1 receptor). E-5842 citrate increases levels of Fos in the medial prefrontal cortex and the nucleus accumbens, without affecting the levels of the protein in the striatum. E-5842 citrate can be used in the research of psychiatric disorders .
    E-5842 citrate
  • HY-124521
    Quinelorane

    LY163502 free base

    		 Dopamine Receptor Neurological Disease
    Quinelorane (LY163502 free base) is a dopamine D2 receptor agonist. Quinelorane promotes semen ejaculation but inhibits penile erection in rats. Quinelorane can be used in the study of sexual dysfunction .
    Quinelorane
  • HY-182713
    Tyrphostin AG-808

    		Tyrosinase Others
    Tyrphostin AG-808 is a protein tyrosine kinase inhibitor that does not reduce neointimal formation. Perivascular implantation of Tyrphostin AG-808 causes medial damage in rats .
    Tyrphostin AG-808
  • HY-183644
    LNO 9

    		Lysyl Oxidase Cardiovascular Disease
    LNO 9 is an orally active LOXL2 inhibitor and NO donor, with an IC50 of 0.17 μM against human LOXL2. LNO 9 competitively binds to the LTQ cofactor of LOXL2 to form an irreversible complex, thereby inhibiting collagen oxidation and abnormal cross-linking. LNO 9 releases nitric oxide (NO) to increase cGMP levels in pulmonary artery smooth muscle cells. LNO 9 inhibits hypoxia-induced collagen modification and possesses vasodilatory activity. LNO 9 ameliorates right ventricular hypertrophy and pulmonary artery medial thickness in rat models induced by hypoxia and Monocrotaline (HY-N0750), and can be used for research on pulmonary hypertension .
    LNO 9
  • HY-W700204
    N-(p-Aminophenethyl)spiperone

    		Dopamine Receptor Neurological Disease
    N-(p-Aminophenethyl) spiperone is a selective D2-like dopamine receptor antagonist. N-(p-Aminophenethyl) spiperone binds to the ligand recognition sites of functional D2 and D3 dopamine receptors. N-(p-Aminophenethyl) spiperone serves as a research tool compound for labeling, localizing and identifying D2 and D3 dopamine receptors .
    N-(p-Aminophenethyl)spiperone
  • HY-179646
    CIAC101

    		Toll-like Receptor (TLR) NO Synthase NF-κB TNF Receptor Interleukin Related Neurological Disease
    CIAC101 is a potent and brain-penetrant TLR4 antagonist with an IC50 of 17.0 nM in NO assay. CIAC101 blocks Lipopolysaccharides (HY-D1056) (LPS)-induced NF-κB activation and reduces the expression of pro-inflammatory mediators (iNOS, IL-1β, TNF-α, and IL-6). CIAC101 robust antineuroinflammatory activity with efficacy against drug-evoked neurobehavioral adaptations. CIAC101 can be used for the research of addiction and neurological disease .
    CIAC101
  • HY-D3420
    Neuro-DiI

    		Fluorescent Dye Neurological Disease
    Neuro-DiI is a red retrograde Fluorescent tracer. Neuro-DiI is transported retrogradely to the cell bodies in the ventral tegmental area and labels ventral tegmental area neurons with red fluorescence .
    Neuro-DiI
  • HY-Y0282
    Sodium bromide

    NSC 77384; Sanibrom 40

    		 Environmental Pollutants Neurological Disease
    Sodium bromide (NSC 77384; Sanibrom 40) is a GABA-ergic system modulator that crosses the blood-brain barrier, and it effectively reduces and blocks epileptiform discharges. Sodium bromide exerts significant anticonvulsant effects by enhancing GABA-ergic inhibitory functions, such as increasing the amplitude of inhibitory postsynaptic currents and paired-pulse inhibition. Sodium bromide specifically enhances stimulation-induced extracellular alkalosis without affecting baseline pH or subsequent acidosis processes. Sodium bromide exhibits species-specific pharmacokinetic characteristics, competes with chloride ions for renal tubular reabsorption sites, and serves as a marker for extracellular fluid volume. Sodium bromide can be used in the research of epilepsy and related neurological diseases .
    Sodium bromide

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: